T-cell prolymphocytic leukemia medical therapy

T-cell prolymphocytic leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating T-cell prolymphocytic leukemia historical perspective from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

T-cell prolymphocytic leukemia medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of T-cell prolymphocytic leukemia medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on T-cell prolymphocytic leukemia medical therapy

CDC on T-cell prolymphocytic leukemia medical therapy

T-cell prolymphocytic leukemia medical therapy in the news

Blogs on T-cell prolymphocytic leukemia medical therapy

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for T-cell prolymphocytic leukemia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:  Qurrat-ul-ain Abid, M.D.[2], Maria Fernanda Villarreal, M.D. [3] Carlos A Lopez, M.D. [4]

## Overview

[edit | edit source]

T-cell prolymphocytic leukemia responds better when combinations of chemotherapy drugs are used. Monoclonal antibodies are a type of biological therapy that has been effective in treating certain types of leukemias. Splenectomy and external beam radiation therapy to the spleen may be used in some people with prolymphocytic leukemia.

## Medical Therapy

[edit | edit source]

* The mainstay of therapy for T-cell prolymphocytic leukemia, include:[1][2]

* Alemtuzumab (anti-CD52)

* T-cell prolymphocytic leukemia is often resistant to therapy.

### Chemotherapy

[edit | edit source]

T-cell prolymphocytic leukemia responds better when combinations of chemotherapy drugs are used. Some combinations that may be used are:[3]

* CVP – Cyclophosphamide, vincristine and prednisone.

* CHOP – Cyclophosphamide, doxorubicin, vincristine and prednisone.

Other chemotherapy drugs (purine analogues) are often used to treat T-cell prolymphocytic leukemia are:

* Fludarabine
* Cladribine
* Pentostatin

### Biological therapy

[edit | edit source]

Monoclonal antibodies are a type of biological therapy that has been effective in treating certain types of leukemias. These drugs may be used alone or in combination with chemotherapy to treat prolymphocytic leukemia.

* Alemtuzumab seems to be particularly effective in treating T-cell prolymphocytic leukemia. It may be used in people whose lymphoma is no longer responding to chemotherapy drugs like fludarabine.

### Splenectomy or radiation therapy to the spleen

[edit | edit source]

Splenectomy and external beam radiation therapy to the spleen may be used in some people with prolymphocytic leukemia.

## References

[edit | edit source]

1. ↑ Graham RL, Cooper B, Krause JR (2013). "T-cell prolymphocytic leukemia". Proc (Bayl Univ Med Cent). 26 (1): 19–21. PMC 3523759. PMID 23382603.
2. ↑ Robak T, Robak P (April 2007). "Current treatment options in prolymphocytic leukemia". Med. Sci. Monit. 13 (4): RA69–80. PMID 17392661.
3. ↑ "Canadian Cancer Society".

Template:WH Template:WS